Amneal Pharmaceuticals, Inc. (AMRX)

NYSE: AMRX · IEX Real-Time Price · USD
2.02
-0.07 (-3.35%)
Sep 30, 2022 4:00 PM EDT - Market closed
-3.35%
Market Cap 613.12M
Revenue (ttm) 2.12B
Net Income (ttm) -133.58M
Shares Out 303.52M
EPS (ttm) 0.01
PE Ratio 202.00
Forward PE 6.30
Dividend n/a
Ex-Dividend Date n/a
Volume 756,102
Open 2.10
Previous Close 2.09
Day's Range 2.02 - 2.14
52-Week Range 2.00 - 5.99
Beta 1.32
Analysts Buy
Price Target 5.92 (+193.1%)
Earnings Date Nov 1, 2022

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in ... [Read more...]

Industry Pharmaceuticals
Founded 2002
Employees 7,000
Stock Exchange NYSE
Ticker Symbol AMRX
Full Company Profile

Financial Performance

In 2021, AMRX's revenue was $2.09 billion, an increase of 5.08% compared to the previous year's $1.99 billion. Earnings were $10.62 million, a decrease of -88.33%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for AMRX stock is "Buy." The 12-month stock price forecast is 5.92, which is an increase of 193.07% from the latest price.

Price Target
$5.92
(193.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial O...

3 weeks ago - Business Wire

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson's Disease

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a n...

1 month ago - Business Wire

Amneal supports Congress' efforts to ensure essential medicines are Made in America

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced its support of the creation of the bipartisan Congressional Domestic Pharmaceuti...

1 month ago - Business Wire

Amneal launches 4 new Generic products, including Vasopressin single-dose

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...

1 month ago - Business Wire

Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates

Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Amneal Reports Second Quarter 2022 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2022. “Solid second quarter re...

1 month ago - Business Wire

Amneal Appoints Deborah M. Autor to Board of Directors

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Deborah M. Autor has been appointed to the Company's Board of Directors, ef...

1 month ago - Business Wire

Amneal to Report Second Quarter 2022 Results on August 5, 2022

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to m...

2 months ago - Business Wire

Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its second annual (2021) Corporate Responsibility Report. The rep...

3 months ago - Business Wire

Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of LYVISPAH®, a baclofen oral granules (5, 10 and 20 mg) s...

4 months ago - Business Wire

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company's Bi...

4 months ago - Business Wire

Amneal to Participate at the 2022 Jefferies Healthcare Conference

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Fina...

4 months ago - Business Wire

Amneal to Participate at Upcoming Investor Conferences in May

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will attend the following investor conference...

4 months ago - Business Wire

Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Amneal Reports First Quarter 2022 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the first quarter ended March 31, 2022. “We are very pleased wit...

4 months ago - Business Wire

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Biol...

5 months ago - Business Wire

Amneal to Report First Quarter 2022 Results on May 4, 2022

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to m...

5 months ago - Business Wire

Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that results from the pivotal Phase 3 RISE-PD clinical trial evaluating the novel investigational extended-r...

6 months ago - Business Wire

Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has been awarded a sub-license from the Medicines Patent Pool (MPP) to manufa...

6 months ago - Business Wire

Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates

Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Amneal Reports Fourth Quarter and Full Year 2021 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2021. “2021 ...

6 months ago - Business Wire

Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License Ap...

7 months ago - Business Wire

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Amneal Expands Injectables Portfolio with 4 New Products

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the approval of four generic injectables products. Dexamethasone sodium phosphat...

7 months ago - Business Wire

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

7 months ago - Zacks Investment Research